Basic Pharma
Basic Pharma is a Netherlands-based pharmaceutical CDMO offering GMP-certified development, manufacturing, and regulatory services for pharmaceutical and biotech companies. It also licenses a proprietary generic product portfolio and operates a biotech division producing research-grade recombinant proteins for global academic and commercial customers.
- Company typePrivate
- Founded2003
- HeadquartersGeleen, Netherlands
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Basic Pharma does
Basic Pharma is a Netherlands-based, privately held pharmaceutical Contract Development and Manufacturing Organization (CDMO) founded in 2003 and headquartered in Geleen. The company operates a single GMP-certified facility offering end-to-end pharmaceutical services spanning formulation development, API manufacturing, analytical testing, regulatory affairs, pharmacovigilance, and commercial production across multiple dosage forms including liquids, semi-solids, nasal sprays, prefilled syringes, and vials. Basic Pharma holds GMP certification from Dutch authorities and ISO 13485:2016 certification, with experienced Qualified Persons enabling QP release for European market supply.
The company operates three integrated business lines. The core CDMO/CMO service line delivers project-based contract manufacturing for pharmaceutical companies from early clinical phase through commercialization. A generic medicinal products division develops formulations in-house and licenses the resulting dossiers (in e-CTD format) to partners across multiple territories, creating a licensing and royalty revenue stream. The Basic Pharma Biotech sub-brand extends CDMO capabilities into biologicals, offering recombinant protein expression services using validated microbial platforms (E. coli, Pichia pastoris, Hansenula polymorpha yeast) with bioreactor capacity from 0.5L to 50L, alongside a catalog of research-grade recombinant proteins (rHSA, Histone H3, sfGFP, TEV Protease, MBP) sold directly to universities, laboratories, and biotech companies worldwide.
Revenue is generated through three channels: professional services fees for CDMO contracts, licensing royalties from generic product partnerships, and direct unit-based sales of catalog biotech products priced between €95 and €1,245. Go-to-market is direct sales-led with engagement via the company website, industry events, and strategic partnerships — notably with Maastricht University for Histone H3 co-development and ARTES Biotechnology for rHSA manufacturing. Customer segments include pharmaceutical companies, biotech companies, academic and research institutions, and generic product licensing partners. The company maintains worldwide delivery capabilities for biotech products and serves pharmaceutical clients globally through direct engagement.
Basic Pharma firmographics
Firmographics- Name
- Basic Pharma
- Legal name
- Basic Pharma
- Website
- https://basicpharma.nl
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Basic Pharma is a Netherlands-based pharmaceutical CDMO offering GMP-certified development, manufacturing, and regulatory services for pharmaceutical and biotech companies. It also licenses a proprietary generic product portfolio and operates a biotech division producing research-grade recombinant proteins for global academic and commercial customers.
- Ownership category
- akta.pro rank
Basic Pharma industry classification
Industry- Product category
- Pharmaceutical CDMO Services
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Small-Molecule Generics (Branded/Unbranded) (HLAIABAA), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)
Keywords
Where Basic Pharma is headquartered
LocationHeadquarters
- HQ city
- Geleen
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
Basic Pharma business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
Revenue model
- CDMO/Contract Manufacturing Services: Full-service contract development and manufacturing services for pharmaceutical products, including formulation development, analytical testing, regulatory support, and commercial manufacturing. Revenue generated through project-based contracts with pharmaceutical and biotech companies.
- Generic Product Licensing: Development and out-licensing of generic medicinal products. Basic Pharma develops products in-house and licenses them to partners in multiple territories. Also offers in-licensing and co-development arrangements.
- Biotech Products (Recombinant Proteins): Sale of research-grade recombinant proteins including Human Serum Albumin, Histone H3, sfGFP, TEV Protease, and MBP. Products are sold directly to universities, laboratories, and biotech companies worldwide with batch-specific CoA documentation.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Human Serum Albumin (rHSA) - Lyophilized recombinant protein from Hansenula polymorpha yeast |
| Unit Pricing | Pay-as-you-go | Histone H3 - Recombinant from E. coli, >95% purity |
| Unit Pricing | Pay-as-you-go | sfGFP - Superfolder GFP recombinant from E. coli, >95% purity |
| Unit Pricing | Pay-as-you-go | TEV Protease - Recombinant cysteine protease |
| Unit Pricing | Pay-as-you-go | Maltose Binding Protein (MBP) - Recombinant from E. coli, >95% purity |
Go-to-market motion3 records
Distribution channels2 records
Marketing channels4 records
Basic Pharma product offering
Product offeringCore offering
Basic Pharma is a full-service pharmaceutical CDMO providing contract development, GMP-compliant manufacturing, analytical laboratory testing, and regulatory consultancy for pharmaceutical companies from lab scale to early clinical phase and beyond. The company maintains an in-house generic medicinal product portfolio available for out-licensing and operates a biotech division that produces research-grade and GMP-grade recombinant proteins via microbial expression systems (E. coli, Pichia pastoris, Hansenula polymorpha) for biotech companies, universities, and laboratories worldwide.
Differentiator
Problem solved
Functional benefit
Brands
- Basic Pharma Biotech: Biotech division focused on recombinant protein expression, production, and purification services for the pharmaceutical and biotechnology industries.
Products and services
- CDMO/Contract Manufacturing Services Full-service contract development and manufacturing organization (CDMO) services covering formulation development, GMP-compliant manufacturing, IMP manufacturing, aseptic fill-finish with isolators for cytotoxic compounds, lyophilization, packaging with FMD serialization, and compounding from lab scale through early clinical phase to commercial production for pharmaceutical and biotech clients.
- Laboratory and Analytical Testing Services ICH-compliant analytical testing services including HPLC (UV, DAD, IR, fluorescence detection), microbiological testing, stability studies across approximately 100 m² of controlled climate chambers, and method development/validation according to Ph. Eur. or USP methods for pharmaceutical clients.
- Regulatory and Scientific Consultancy Services Expert consultancy in regulatory affairs, quality assurance, pharmacovigilance, and clinical research, supporting pharmaceutical clients in navigating market authorization and product development pathways.
- In-house Generic Medicinal Product Portfolio (Out-licensing) Portfolio of in-house developed generic prescription and OTC medicinal products, available for out-licensing to partners across multiple territories, with product dossiers in e-CTD format and supported by in-licensing and co-development arrangements.
- Recombinant Protein Catalog Products Catalog of research-grade recombinant proteins including Human Serum Albumin (rHSA, Hansenula polymorpha), Histone H3 (E. coli), sfGFP (E. coli), TEV Protease, and Maltose Binding Protein (MBP), each supplied lyophilized with batch-specific Certificates of Analysis to universities, laboratories, and biotech companies worldwide.
- Custom Recombinant Protein Expression and Bioprocess Services Bespoke contract services for recombinant protein expression and bioprocess development using BSL-2 microbial expression systems in E. coli, Pichia pastoris, and Hansenula polymorpha, with bioreactor capacity ranging from 0.5L to 50L, bioprocess homogenization up to 1200 bars, chromatography at R&D and pilot scale, tangential flow filtration, and lyophilization for biotech clients from R&D to preclinical and pilot scale.
Quantifiable outcome
- Stable product development with climate chambers maintaining temperature and humidity control for ICH stability studies
- +1 more outcomes
Companies that use Basic Pharma
Customer profileSegments4 records
Ideal customer profiles4 records
Basic Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Basic Pharma partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Maastricht UniversitycoreCollaboration for the development and manufacturing of recombinant Histone H3. Combines expertise of an academic research institute with an industrial company in protein engineering. The Histone H3 product is produced using Basic Pharma's E. coli expression platform developed in partnership.
- ARTES BiotechnologycoreCollaboration for the development and manufacturing of recombinant Human Serum Albumin (rHSA). ARTES Biotechnology contributes expertise in yeast-based protein expression using Hansenula polymorpha, while Basic Pharma provides GMP manufacturing capabilities and commercial distribution.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
Basic Pharma competitors and assessment
Company assessmentOthers
Direct peers
- Recipharm: European CDMO providing development, manufacturing, and analytical services across multiple dosage forms including sterile injectables and inhalation products. Comparable to Basic Pharma in its full-service pharma CDMO offering and European customer base.
- Aenova Group: European mid-sized CDMO offering solid, semi-solid, and liquid dosage form development and manufacturing including softgel and sterile capabilities. Directly comparable to Basic Pharma in integrated small-molecule CDMO services for pharma and biotech customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Basic Pharma social profiles
Digital presenceBasic Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Basic Pharma leadership team
Management profileNumber of profiles
Profiles3 records
Basic Pharma funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Basic Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Basic Pharma
What does Basic Pharma do?
Basic Pharma is a full-service pharmaceutical CDMO providing contract development, GMP-compliant manufacturing, analytical laboratory testing, and regulatory consultancy for pharmaceutical companies from lab scale to early clinical phase and beyond. The company maintains an in-house generic medicinal product portfolio available for out-licensing and operates a biotech division that produces research-grade and GMP-grade recombinant proteins via microbial expression systems (E. coli, Pichia pastoris, Hansenula polymorpha) for biotech companies, universities, and laboratories worldwide.
Is Basic Pharma a public or private company?
Basic Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Basic Pharma founded?
Basic Pharma was founded in 2003. It employs 101 to 250 people.
Where is Basic Pharma based?
Basic Pharma is headquartered in Geleen, Netherlands, in the Europe region.
How does Basic Pharma make money?
Three revenue lines are on record. CDMO/Contract Manufacturing Services are the primary driver. The others are generic Product Licensing and biotech Products (Recombinant Proteins).
Who are Basic Pharma's main competitors?
Hovione is listed as an others. Direct peers are Recipharm and Aenova Group.
Does Basic Pharma have an API?
No public API is recorded for Basic Pharma.
What industry is Basic Pharma in?
Basic Pharma's product category is Pharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC). Its NAICS code is 325412 and its SIC code is 2834.